Cargando…

Opportunities and challenges for antisense oligonucleotide therapies

Antisense oligonucleotide (AON) therapies involve short strands of modified nucleotides that target RNA in a sequence‐specific manner, inducing targeted protein knockdown or restoration. Currently, 10 AON therapies have been approved in the United States and Europe. Nucleotides are chemically modifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuijper, Elsa C., Bergsma, Atze J., Pijnappel, W.W.M. Pim, Aartsma‐Rus, Annemieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Ssiem Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891411/ https://www.ncbi.nlm.nih.gov/pubmed/32391605 http://dx.doi.org/10.1002/jimd.12251

Ejemplares similares

From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
por: Bergsma, Atze J, et al.
Publicado: (2016)

Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
por: van der Wal, Erik, et al.
Publicado: (2017)

Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects
por: Baruteau, Julien, et al.
Publicado: (2017)

From structural biology to designing therapy for inborn errors of metabolism
por: Yue, Wyatt W.
Publicado: (2016)

A primer to gene therapy: Progress, prospects, and problems
por: Zittersteijn, Hidde A., et al.
Publicado: (2020)

Stem cell therapy for white matter disorders: don’t forget the microenvironment!
por: Dooves, Stephanie, et al.
Publicado: (2016)

Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I
por: Penati, Rachele, et al.
Publicado: (2017)

Sirtuin activation as a therapeutic approach against inborn errors of metabolism
por: Bleeker, Jeannette C., et al.
Publicado: (2016)

Amino acid synthesis deficiencies
por: de Koning, T. J.
Publicado: (2017)

Redox signalling and mitochondrial stress responses; lessons from inborn errors of metabolism
por: Olsen, Rikke K. J., et al.
Publicado: (2015)

The important role of biochemical and functional studies in the diagnostics of peroxisomal disorders
por: Ferdinandusse, Sacha, et al.
Publicado: (2016)

Mitochondrial transcript maturation and its disorders
por: Van Haute, Lindsey, et al.
Publicado: (2015)

Moving towards clinical trials for mitochondrial diseases
por: Pitceathly, Robert D.S., et al.
Publicado: (2020)

Introduction to the Komrower Memorial Lecture 2010
por: Jakobs, Cornelis
Publicado: (2011)

SSIEM reflections 2004–2010: the growing stature of our society
por: Jakobs, Cornelis
Publicado: (2010)

Spectrum of combined respiratory chain defects
por: Mayr, Johannes A., et al.
Publicado: (2015)

Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience
por: Jaeger, Bregje, et al.
Publicado: (2016)

MtDNA-maintenance defects: syndromes and genes
por: Viscomi, Carlo, et al.
Publicado: (2017)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Nonclinical Exon Skipping Studies with 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn−/− Mice Inspired by Clinical Trial Results
por: van Putten, Maaike, et al.
Publicado: (2019)

Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities
por: Lange, Jenny, et al.
Publicado: (2022)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
por: Hammond, Suzan M, et al.
Publicado: (2021)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
por: Veltrop, Marcel, et al.
Publicado: (2018)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies
por: Aerts, Johannes M. F. G., et al.
Publicado: (2011)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011
por: Cornel, Martina C., et al.
Publicado: (2012)

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor
por: Kemaladewi, Dwi U, et al.
Publicado: (2014)

Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
por: Jirka, Silvana M.G., et al.
Publicado: (2018)

Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability
por: Olpin, Simon E
Publicado: (2013)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI
por: Broeders, Mike, et al.
Publicado: (2020)

Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva
por: Shi, SongTing, et al.
Publicado: (2013)

The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice
por: Verhaart, Ingrid E C, et al.
Publicado: (2014)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ojv8sqcnuh648hkgvr4jfg4llo